Rituximab, a lower-cost treatment, may be as effective at managing RRMS as the approved therapy Ocrevus, a new study from ...

In Phase III MINT trial, Uplizna (inebilizumab) demonstrated significant short-term efficacy and a manageable safety profile ...

Roche’s bispecific antibody, Columvi receives European approval for diffuse large B-cell lymphoma after initial therapy: Basel Tuesday, April 15, 2025, 10:00 Hrs [IST] Roche ann ...

Additional information on these clinical trials can be found at www.clinicaltrials.gov (NCT03277261; NCT03277248). BRIUMVI is a novel monoclonal antibody that targets a unique epitope on ...

Additional information on these clinical trials can be found at www.clinicaltrials.gov (NCT03277261; NCT03277248). BRIUMVI is a novel monoclonal antibody that targets a unique epitope on ...

The findings reinforce the potential of BRIUMVI in improving patient outcomes for those seeking an alternative to their previous anti-CD20 therapy. Furthermore, the article in CNS DRUGS offers an ...

The approval of the Columvi combo, the first bispecific antibody regimen for DLBCL in Europe, follows a conditional marketing ...

Lyell Immunopharma (LYEL) announced that the U.S. Food and Drug Administration granted Regenerative Medicine Advanced Therapy, RMAT, ...

Title: The Evolution of Anti-CD20 Treatment for Multiple Sclerosis ... The discussion of these refinements includes improving the extent of B-cell depletion, reducing infusion-related reactions ...